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Abstract: 
Background and study aims: The transnasal endoSheath endoscope (TEE) is a new disposable 
technology with potential applicability to primary care setting. To evaluate the efficacy of 
this new technology for detection of Barrett’s Oesophagus (BO), this study compared the 
diagnostic accuracy of TEE with standard endoscopy (SE). 
Patients and methods: This was a prospective, randomized, cross-over study performed in a 
single, tertiary referral center. Consecutive patients undergoing surveillance for BO or 
referred for diagnostic assessments were recruited. All patients were randomized to have 
TEE followed by SE or the reverse.  Endoscopic experiences and patient preferences were 
evaluated using a single questionnaire. Endoscopic and histologic diagnosis of BO, including 
optical image quality of both endoscopic procedures were compared. 
Results: 21 of 25 patients completed the study. TEE had sensitivity and specificity of 100% 
for an endoscopic diagnosis of BO and of 66.7% and 100%, respectively, for histologic 
diagnosis of BO.  Mean optical quality of SE was significantly better than TEE (7.11± 0.42 
vs.4.06± 0.27), (p <0.0001). However, following endoscopy patients reported a significantly 
better experience with TEE compared to SE (7.05 ± 0.49 vs. 4.35± 0.53), (p = 0.0006) with 
60% preferring TEE and 25% sedated SE.  
Conclusions: In this study TEE had equal accuracy for an endoscopic diagnosis of BO 
compared to SE, at the expense of reduced image quality and a lower yield of intestinal 
metaplasia (IM) on biopsy. TEE was better tolerated and preferred by patients. Hence, TEE 
needs further evaluation in primary care as an initial diagnostic tool.  
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Introduction 
The incidence of oesophageal adenocarcinoma (OAC) has increased dramatically in Western 
Countries over the last 30 years. However, despite advances in staging and treatment 
strategies, the 5-year survival of patients with this diagnosis remains poor, indicating the 
need to detect this cancer early to improve outcomes [1, 2]. Barrett’s oesophagus (BO) is the 
only recognized precursor to this cancer and can be monitored over time endoscopically 
with the aim to detect neoplastic changes at an early curable stage. Retrospective series 
have showed that endoscopic surveillance of BO leads to early detection of EAC at an earlier 
clinical stage [3, 4], however the data on survival benefit remains controversial [5, 6]. The 
discrepancy among studies can be explained by the evidence that surveillance only improves 
survival from OAC if it is conducted with strict adherence to the recommended protocol [7]. 
Within this context, screening programs for BO have the potential to reduce mortality from 
OAC.  
A valid screening test needs to be cheap, accurate, well tolerated and applicable to primary 
care [8]. Currently, the only validated screening test for BO is standard endoscopy (SE), 
which has major limitations. It requires sedation that increases the risk of adverse events, 
prolongs the length of the procedure and adds direct and indirect costs [9-11]. In addition, 
the standard endoscopic equipment requires decontamination, which is labour intensive, 
time consuming, with additional costs related to reprocessing machines. Hence, population 
screening by SE remains controversial, and specialist societies recommend it only in high risk 
individuals [12, 13]. 
Unsedated ultrathin transnasal endoscopy has been shown to be feasible, well tolerated, 
safe and accurate in evaluating BO [14-16]. In addition, TNE is estimated to be cost-effective 
compared with SE [17]. However, these endoscopes require the same decontamination 
process as standard endoscopes. A novel transnasal endoSheath® endoscope (TEE) has been 
developed to circumvent the need for reprocessing and allow use in a portable office-based 
setting.  It has a reusable ultrathin endoscope with an outer disposable sterile sheath. The 
processor, light source and screen are integrated in a portable digital processing unit with 
the size of a briefcase. The TEE system has not yet been evaluated in a randomized cross-
over design for the diagnosis of BO. 
The primary aim of the study was to evaluate the sensitivity and specificity of TEE in 
diagnosing BO with reference to the endoscopic diagnosis made by SE; 
The secondary aims of the study were: 
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1. To evaluate the sensitivity and specificity of TEE for a histologic diagnosis of BO with 
intestinal metaplasia  with reference to the histopathology assessed on two random biopsies 
taken during SE  
2. To compare the optical quality of TEE with SE; 
3. To compare the patient tolerability and preference for the two procedures. 
 
Patients and Methods 
Design and Participants 
This was a prospective randomized cross-over study performed in a tertiary referral centre. 
The study was approved by the Cambridgeshire 2 research ethics committee, Cambridge, 
U.K. All patients were over the age of 18 years and provided individual, informed consent for 
the study. 
Two groups of patients were eligible for this study: a) Patients who were scheduled to have 
a diagnostic endoscopy for indications including dyspepsia, anaemia, suspected coeliac 
disease and abdominal pain, who were not known to have BO and b) Patients with a 
previous diagnosis of BO with a minimum length of at least 2 cm. This length cut-off was 
chosen to limit the impact of very short segments or an irregular Z-line which are known to 
lead to poor diagnostic agreement [18, 19]. However, if at the time of the research 
endoscopy their BO was found to be shorter than 2cm, they would still be included in the 
study. 
Exclusion criteria were: 
Known upper GI tract abnormality (e.g. pharyngeal pouch or previous 
esophageactomy); 
Coagulopathy or anticoagulant treatment; 
Active or severe cardiopulmonary or liver disease; 
Active GI bleeding; 
Referral to fast track service with alarm symptoms or dysphagia; 
High grade dysplasia or intramucosal carcinoma in BO requiring extensive evaluation 
and biopsy. 
After written informed consent was obtained, randomization was performed using a 
computer-generated randomization (www.randomization.com web-site), which allocated 
patients on a 1 to 1 basis to TEE followed by SE (“TEE first” group) or the reverse order of 
investigations (“SE first” group). The two procedures were performed by different 
endoscopists. The second procedure was undertaken at least 2 weeks later to allow for 
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mucosal healing if biopsies had been taken, thus ensuring that the endoscopists were blind 
to the indication. For practical reasons, the endoscopists were assigned to the first or second 
procedure based on their availability and not by a second independent randomization; 
however endoscopists were blind to the order of the procedures and were provided with 
the same clinical information. In addition the endoscopists were blinded to the indication to 
the procedure and the outcome of the other endoscopy test. A dedicated research nurse 
was present at all procedures to maintain the blinding of both the order and indication of 
procedure. 
 
Endoscopy procedures 
All SE procedures were performed by three experienced endoscopists (MKS, SV and MDP). 
The TEE procedures were performed by two endoscopists (MKS or SV), who had performed 
at least 50 procedures prior to the study. 
 
Ultrathin unsedated Transnasal EndoSheath® Endoscopy (TEE): the EndoSheath® technology 
( TNE – 5000) consists of a ‘D’ shaped ultrathin scope (outer diameter of 4.7mm x 5.8mm) 
with a working length of 650mm, a two way distal angulation (140⁰ up and 215⁰ down) and a 
disposable sheath with two channels for insufflation, suction and biopsy forceps (Vision® 
Sciences, Inc, New York, USA). The endoscope handle has two push buttons to control 
insufflation and suction. Prior to each procedure the endoscope was placed in the sterile 
disposable sheath The patient’s nasal cavity was sprayed with a combination of a local 
anaesthetic and decongestant and the procedure was performed in the sitting or left lateral 
position. The examination was limited to the oesophagus and the proximal stomach. 
Endoscopists located the following landmarks and made a note of their distance from the 
nares: (a) the diaphragmatic pinch; (b) the gastro-esophageal junction (GEJ), corresponding 
to the  top of the proximal gastric folds on minimal distension[19] , and (c) the squamo-
columnar junction  or ‘Z’ line[20]. A still image of the ‘Z’ line or the BO segment was taken to 
evaluate the optical quality. On endoscopic evidence of columnar-lined oesophagus 2 
targeted biopsies were taken with a paediatric biopsy forceps within the BO segment to look 
for intestinal metaplasia (IM). 
 
Standard endoscopy (SE): was performed using a 9.8 mm diameter endoscope (GIF-Q240Z, 
Olympus Inc.) with complete intubation of the second part of the duodenum according to 
standard practice. The procedure was performed under local anaestheticLidocaine spray 
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(Xylocaine®, Astrazeneca, U.K.) or conscious sedation using midazolam according to patient 
preference as per standard practice. If BO was detected 2 biopsies were taken within the 
segment of columnar-lined oesophagus to compare with TEE for presence of IM. This was 
followed by surveillance biopsies taken according to the Seattle protocol[21]. This allowed 
for direct comparison between TEE and SE without subjecting BO patients to two sets of 
surveillance biopsies. Still images of the ‘Z’ line and BO were captured as mentioned above. 
Any serious adverse events related to both procedures were recorded. Any failure to 
complete the procedure, including the reason for the failure, was recorded by the 
endoscopist.   
 
Diagnostic criteria: a hiatal hernia was documented as viewed on the instructional video 
available on the international working group website for the classification of oesophagitis 
(www.iwgco.org) and the length was recorded according to the Prague C&M 
classification[19]. For the analysis the maximal length was used. The presence of 
oesophagitis was documented using the LA Classification [11]. Biopsies were evaluated by a 
single expert GI pathologist (MO’D) who was blinded to the endoscopic findings and 
endoscopy type, according to 2005 British Society of Gastroenterology guidelines [22], since 
this study was completed prior to the publication of the most recent 2014 guidelines [12]. 
 
Optical quality: The still images taken at both procedures were transferred onto Microsoft 
power point maintaining the same quality. The images were placed in a random order and 
evaluated by MDP and SV. The quality of the image was scored on a 10-cm visual analogue 
scale with 10 being excellent and 0 poor (VAS)[16]. The evaluators were asked to comment 
on the presence or absence of BO on TEE to estimate the interobserver agreement.   
 
Patient acceptability: Following both of the procedures the participants completed a 10-
point visual analogue scale (VAS), where 0 represented the worst experience and 10 the best 
experience ever. One week (+/- 2 days) after the completion of both the procedures patients 
were asked a single question addressing preferences for endoscopy.   
 
Statistics: Continuous data were reported as mean with standard error of mean (SEM) or as 
median with range according to the type of distribution of variables. To compare groups 
Student’s t test and Chi-square was used depending on the variables. All P-values were 2-
sided and assumed to be significant if p ≤ 0.05. Statistical analyses were performed using 
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GraphPad Prism 6 (La Jolla, CA, USA). Bland and Altman’s limits of agreement method was 
used to assess agreement of the two procedures in assessing the length of BO. For the 
endoscopic findings, the diagnosis made by SE was regarded as the reference. For the 
pathological findings, the histology based on the 2 research biopsies taken at SE was 
regarded as the reference. The sensitivity, specificity and diagnostic accuracy for detecting 
BO using TEE when compared to the reference SE was calculated along with 95% Clopper-
Pearson confidence intervals. Interobserver agreement was estimated using k values with 
95% confidence intervals. 
The study was powered to address the primary aim of the study (endoscopic diagnosis of 
BO). Previous studies have showed that TNE has a sensitivity and a specificity for Barrett’s of 
90% and 95% [23-26]. Even though this may not be directly applicable to the TEE technology, 
we used this information to calculate the sample size. With this level of diagnostic accuracy 
we expected to recruit at least 12 patients with BO and 7 patients without BO to show a 
sensitivity and a specificity of at least 0.65 or better at a significance level of 0.05. 
Briefly, if we assume that the true sensitivity is 90%, then testing 12 BO patients will result in 
at least 11 positive test results with a probability of 69.8%. In this case, the one-sided upper 
tail of a binomial distribution, under the null hypothesis of a sensitivity of 65% or less, results 
in a p-value of 0.042 or less. Under these circumstances, we will be able to demonstrate a 
sensitivity of at least 0.65 at a significance level of 0.05. Similarly, when recruiting 7 patients 
without BO and assuming a true specificity of 0.95, we anticipate 7 negative test results with 
a probability of 65.9%. Under these circumstances we will be able to demonstrate a 
specificity of at least 65% with a p-value of 0.049, obtained from the upper tail of the 
binomial distribution. 
 
Results  
Recruitment and participants 
98 patients who fulfilled the criteria for inclusion were approached and 25 consented to 
participate in the study. Among those who declined participation, 20 patients were 
specifically asked to disclose the reason and the two main motivations were time constrains 
to commit for a second visit and the reluctance to have a second procedure. Four withdrew 
from the study, 3 after SE and 1 after TEE, none of whom had BO. 21 patients completed 
both the procedures. Patient demographics are shown in Table 1. 
Diagnostic accuracy and optical quality of TEE 
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13 participants had endoscopic evidence of BO on SE and all these cases were correctly 
detected by TEE, which yielded a sensitivity and specificity of 100% for an endoscopic 
diagnosis of BO by TEE (95% CI, 75.3 – 100%) (Table 2). Biopsies taken at SE found 
histological evidence of IM in 9 cases [69.2% (9/13)] of which 6 were also confirmed by 
biopsies taken at TEE. This translated into a sensitivity and specificity of 66.7% (95% CI, 29.9 
– 92.5%) and 100% (95% CI, 79.4 – 100%), respectively (Table 2). Of the three cases in which 
IM was not detected on TEE-directed biopsies, two had short tongues of columnar-lined 
oesophagus (C0M1),of which in one case no biopsies were taken due to the difficulty in 
targeting the sampling, and the other was a C1M2 segment.  
The median length of BO was 3cm (interquatile range [IQR] 1.5-4 cm) on SE and 2 cm on TEE 
(IQR 1-3 cm) The agreement between TEE and the reference standard SE is shown in figure 
1.Overall we found a good level of agreement, with a discrepancy between the two 
technologies which is not dissimilar from the reported inter- and intra-observer variability 
for BO length estimation on SE [18]. In addition there was no trend in the difference of 
length between the procedures excluding systematic error 
16 images were available for evaluation of optical quality. The mean optical quality score as 
measured by VAS for SE was 7.11 (SEM ± 0.42). This was significantly better than the mean 
optical quality of TEE, which was 4.06 (SEM ± 0.27) (p = <0.0001) (Fig 2 and 3). The 
interobserver agreement for diagnosis of BO on TEE endoscopic images between the two 
endoscopists was good with a Κ of 0.738 (95% CI, 0.41 to 1.00). 
Patient endoscopic experience and preference  
Of the 21 patients that completed the study, 20 completed the post endoscopy visual 
analogue experience scale. The patient reported endoscopy experience following TEE was 
7.05 (SEM ± 0.49). This was significantly better than the level of experience following SE 
of4.35 (SEM ± 0.53), (p = 0.0006) (Fig 4A). Following the second endoscopy 20 patients 
returned their endoscopy preference questionnaire. 12 participants (60%) reported a 
preference for TEE with local anaesthesia, 5 (25%) preferred SE with sedation and 3 (15%) 
had no preference (Fig 4B). Among the patients who preferred TTE, one third (n=4) had SE 
under sedation, whereas all patients who preferred SE over TTE had their clinically indicated 
diagnostic procedure under sedation. None preferred SE without sedation. Common 
comments recorded by those who preferred TEE were “nasal felt less intrusive”, “easier to 
tolerate” and “I was able to talk”. 
 
Discussion 
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This is the first study to look at the accuracy of TEE to diagnose BO in a randomized design. 
Our study demonstrates that TEE is as good as SE for an endoscopic diagnosis of BO with a 
sensitivity and specificity of 100%, even with a lower optical quality. The instrument allows 
for the use of paediatric sized biopsy forceps and can detect IM with a sensitivity and 
specificity of 0.67 and 1.00, respectively. Patients tolerated TEE significantly better than SE 
and most preferred TEE. 
There are only two other studies which investigated the same technology used in this trial. 
One of these evaluated the feasibility of the endoscopic system, the time taken for 
processing and carrying out the procedures and the safety of TEE compared to SE. This study 
found that  TEE significantly reduced the total time (time to set up, perform procedure and 
reprocess the endoscope) needed to perform upper GI endoscopy when compared to SE 
(18.8 vs 56.4 minutes, p= < 0.05), without compromising safety [27]. A more recent cross-
sectional study on acohort of 426 patients evaluated TEE feasibilty, safety and tolerability 
within a screening setting in tertiary care. TEE was able to diagnose BO in 4% of the 
participants and was tolerated well with only 0.7% reporting minor epistaxis and 0.2% 
reporting nasal irritation [28]. However, this study aimed toscreen for esophageal 
pathologies in general and did not specifically look at  detection of BO. Of the 426 
participants included in this study, only 18 cases of BO were detected by TEE. Also, patients 
did not receive a standard endoscopy, therefore the study did not investigate the diagnostic 
accuracy of TEE as compared with the current gold standard. The results of our study are 
similar to those of previous trials using different types of ultrathin transnasal endoscopy. 
Four non-randomized studies reported a sensitivity and specificity for histologic or 
endoscopic diagnosis of BO of >89% and >95%, respectively [23-26]. However, one study 
which used an ultrathin calibre size of 3.1mm reported a sensitivity of 55% [29]. Two 
additional studies evaluated transnasal endoscopy using a similar design to the present 
study and demonstrated a sensitivity of 83.3% to 91% for detection of BO [15, 16]. In these 
studies patient tolerability of transnasal endoscopy was similar to SE and preference for 
transnasal endoscopy varied between  59% to 71%.  There are some differences between 
this study and the two randomized studies previously published.  First, we used a disposable 
system, totally applicable to primary care, as opposed to a TNE that needs reprocessing. 
Secondly, the scope diameter of the present study was 4.7mm x 5.8mm, compared to a 
5.1mm used in the above studies. 
The findings related to the quality of the image point to the fact that TEE is significantly 
inferior to the SE. While this is expected due to the obvious technological differences and 
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perhaps within an acceptable limit for a screening test, it is possible that this study has 
underestimated the image quality as its assessment was done on still images rather than 
videos. Future studies on this technology should assess optical quality based on video 
sequences.  
This study has some limitations. First, we had a small number of participants, which may bias 
the results in favour of TEE. It is important to test new technologies in pilot randomized 
studies before proceeding to larger multicenter trials. We had difficulty in recruiting patients 
to the study and from our analysis of questionnaires; we found that the main barrier to 
recruitment was the reluctance by patients to undergo two procedures, rather than the 
reluctance to have TEE. Second, the endoscopists were not randomized to the type of 
procedure due to practical reasons, however the two endoscopists performing TEE did an 
equal number of cases (n=11). In addition, a dedicated research nurse was present 
throughout the procedures and ensured that the endoscopists were blinded to the 
indication and the order of endoscopy.  Third, all endoscopists worked in tertiary care with a 
special interest in BO and the cases of BO included were artificially high due to enrichment, 
hence the results of this study cannot be  generalized to a primary care setting for which this 
technology is intended. Fourth, three participants who had SE first withdrew from the study; 
if all of them had preferred SE this would drop the percentage of preference for TEE from 
60% to 45%. Finally, the comparison between SE and TEE for the histologic diagnosis relied 
only on two random biopsies each rather than on the full biopsy protocol. This was decided 
a priori to avoid submitting patients to two consecutive endoscopies with multiple biopsies. 
The limited number of samples may in part explain the lower sensitivity of TEE compared to 
SE for a histologic diagnosis of BO  and the wide 95% CI, considering that the distribution of 
IM in BO is patchy and subject to sampling error. However, it should be noted that the lower 
yield of IM by TEE would preclude its use as surveillance tool. It is reasonable to hypothesize 
that with a sufficient number of biopsies the sensitivity and the 95% CI of TEE for a histologic 
diagnosis of BE might improve.  
This study did not aim to assess diagnostic accuracy for other oesophageal diseases, which is 
relevant when the technology is intended as screening modality in primary care. We have 
looked at other oesophageal findings in our small patient cohort and the only other 
diagnoses made by SE were one case of grade A oesophagitis, which was correctly identified 
and graded by the TEE, and one proximal oesophageal web which was missed by the TEE. 
Future studies will need to address this important issue.  
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Other non-endoscopic imaging technologies that have been tested for BO screeningin 
comparative clinical studies include the esophageal video capsule, and tethered capsule 
endomicroscopy. The esophageal capsule suffers from low sensitivity and specificity for 
diagnosing BO (78% and 73% respectively), requires further endoscopy with biopsy, is 
expensive and applicable mainly to secondary care [30]. The tethered capsule 
endomicroscopy has recently been proposed as a screening device for BO, but the 
interpretation of the imaging output is not straightforward and formal studies are yet to be 
conducted to prove its feasibility [10].  
In conclusion, our pilot study has shown that TEE allows accurate diagnosis of BO. TEE can be 
safely performed without sedation and, given its portability, it is potentially feasible as 
screening tool in primary care and may be used in office-based setting. It will be interesting 
in the future to compare accuracy, acceptability and costs of TEE with other screening tests.  
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Table 1 – Participant demographics 
Table 2 – The efficacy of TTE for detecting endoscopic BO and IM, compared to SE 
Figure 1 – The agreement between TEE and SE for estimation of BO length was analysed 
with a Bland-Altman plot. The dotted lines represent the 95% CI of limits of agreement.  
Figure 2 – Comparison of the mean optical quality scores (on visual analogue scale) of TEE 
and SE 
Figure 3 – Representative endoscopic images of normal GEJ and BO as seen on TEE and SE 
Figure 4 – Endoscopy experience and preference. A) The mean post endoscopy experience 
scores following TEE and SE, B) Preference of type of endoscopy as recorded by participants 
following the last endoscopy 
 
 
Table 1 
 SE first  TEE first  Total  P Value  
Number of patients 12  13  25   
Median age (range)  58.5 (24-76)  58.5 (33-74)  58.5 (24-76)  p=0.90  
Male: Female (ratio)  5:7 (0.56)  10:3 (3.9)  15:10 (2.6)  p=0.11 
 
 
Table 2 
 Sensitivity % 
(95 % CI) 
Specificity % 
(95 % CI) 
Diagnostic accuracy % 
(95 % CI) 
15 
 
Endoscopic BO 100.0 
(75.3 – 100.0) 
100.0 
(73.5 – 100.0) 
100.0 
(86.3 – 100.0) 
Histologically 
confirmed BO 
66.7 
(29.9 – 92.5) 
100.0 
(79.4 – 100.0) 
88.0 
(68.8 – 97.5) 
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Figure 3 
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Figure 4 
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TEE – transnasalendosheath endoscopy; SE – standard endoscopy;  
BO – Barrett’s oesophagus; GEJ – gastroesophageal junction 
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